Versatility of Atrial Flow Regulator Device in Congenital Heart Disease: A Case Series.
AFR
Atrial Flow Regulator Device
Congenital heart disease
Pulmonary hypertension
Journal
Pediatric cardiology
ISSN: 1432-1971
Titre abrégé: Pediatr Cardiol
Pays: United States
ID NLM: 8003849
Informations de publication
Date de publication:
16 Feb 2023
16 Feb 2023
Historique:
received:
09
12
2022
accepted:
02
02
2023
entrez:
16
2
2023
pubmed:
17
2
2023
medline:
17
2
2023
Statut:
aheadofprint
Résumé
The Atrial Flow Regulator (AFR) is a self-expandable double-disk device with a central fenestration, intended to maintain a calibrated communication across the interatrial septum. Only case reports and small case series have been published about its use in the pediatric and congenital heart disease (CHD) population. We described AFR implantation in three congenital patients with different anatomies and indications. In the first case, the AFR was deployed to create a stable fenestration in a Fontan conduit, while in the second, it was used to reduce a Fontan fenestration. In the third case, we implanted an AFR to decompress the left atrium of an adolescent with complex CHD in natural history, with complete mixing, ductal-dependent systemic circulation and combined pulmonary hypertension. This case series demonstrates the great potential of the AFR device in the CHD field, showing versatility, efficacy, and safety in establishing a calibrated and stable shunt, with promising hemodynamic and symptomatic benefits.
Identifiants
pubmed: 36795121
doi: 10.1007/s00246-023-03123-y
pii: 10.1007/s00246-023-03123-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Horizon 2020 Marie Skłodowska-Curie Actions programme within the PremAtuRe nEwborn motor and cogNitive impairmenTs: Early diagnosis (PARENT) project
ID : Grant number 956394
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Paitazoglou C, Bergmann MW, Özdemir R et al (2021) One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail 23(5):800–810
doi: 10.1002/ejhf.2119
pubmed: 33555114
Paitazoglou C, Bergmann MW (2020) The atrial flow regulator: current overview on technique and first experience. Ther Adv Cardiovasc Dis 14:1753944720919577
doi: 10.1177/1753944720919577
pubmed: 32972299
pmcid: 7522821
Sivakumar K, Rohitraj GR, Rajendran M et al (2021) Study of the effect of Occlutech Atrial Flow Regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension. Pulm Circ 11(1):2045894021989966
doi: 10.1177/2045894021989966
pubmed: 33614019
pmcid: 7869179
Dąbrowska-Kugacka A, Ciećwierz D, Żuk G (2019) Atrial flow regulator for severe drug resistant pulmonary arterial hypertension after congenital heart defect correction. Cardiol J 26(1):102–104
doi: 10.5603/CJ.2019.0016
pubmed: 30882193
pmcid: 8086679
Hansmann G, Sabiniewicz A, Sabiniewicz R (2022) Atrial flow regulator for postcapillary pulmonary hypertension: first-in-human transcatheter AFR device implantations in RCM. JACC Case Rep 4(14):878–884
doi: 10.1016/j.jaccas.2022.05.010
pubmed: 35912333
pmcid: 9334142
Lehner A, Schulze-Neick I, Haas NA (2018) Creation of a defined and stable Fontan fenestration with the new Occlutech Atrial Flow Regulator (AFR®). Cardiol Young 28(8):1062–1066
doi: 10.1017/S1047951118000720
pubmed: 29972113
Pascall E, Jones MI, Savis A et al (2021) Transcatheter creation of a pulmonary artery to left atrial fenestration in a failing Fontan circulation using the atrial flow regulator (AFR). Cardiol Young 31(8):1376–1379
doi: 10.1017/S1047951121000731
pubmed: 33766177
Manuri L, Calaciura RE, De Zorzi A et al (2018) Atrial flow regulator for failing Fontan circulation: an initial European experience. Interact Cardiovasc Thorac Surg 27(5):761–764
doi: 10.1093/icvts/ivy165
pubmed: 29860487
Aregullin EO, Samuel B, Vettukattil J (2021) Planned reduction in Fontan fenestration size using the atrial flow regulator. Cardiol Young 31(10):1690–1692
doi: 10.1017/S104795112100127X
pubmed: 33843522
O’Callaghan B, Zablah J, Vettukattil J (2022) Multi-Institutional US Experience of the Occlutech© AFR device in congenital and acquired heart disease. Congenit Heart Dis 17(1):107–116
doi: 10.32604/CHD.2022.018590
Khajali Z, Ghaderian H, Firoozi A et al (2020) New horizon of intervention in congenital heart disease: AFR in a Complex cyanotic patient. Case Rep Cardiol 23(2020):8897101
Piccinelli E, Castro-Verdes MB, Fraisse A et al (2021) Implantation of an atrial flow regulator in a child on venoarterial extracorporeal membrane oxygenator as a bridge to heart transplant: a case report. J Card Fail 27(3):364–367
doi: 10.1016/j.cardfail.2020.11.006
pubmed: 33242607
Shah SJ, Borlaug BA, Chung ES et al (2022) Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet 399(10330):1130–1140
doi: 10.1016/S0140-6736(22)00016-2
pubmed: 35120593
The Prophet Trial—Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension. ClinicalTrials.gov Identifier: NCT03022851.
Lemler MS, Scott WA, Leonard SR et al (2002) Fenestration improves clinical outcome of the Fontan procedure: a prospective, randomized study. Circulation 105:207–212
doi: 10.1161/hc0202.102237
pubmed: 11790702
Daley M, Buratto E, King G et al (2022) Impact of Fontan fenestration on long-term outcomes: a propensity score-matched analysis. J Am Heart Assoc 11(11):e026087
doi: 10.1161/JAHA.122.026087
pubmed: 35621213
pmcid: 9238726
Ono M, Boethig D, Goerler H et al (2006) Clinical outcome of patients 20 years after Fontan operation—effect of fenestration on late morbidity. Eur J Cardiothorac Surg 30:923–929
doi: 10.1016/j.ejcts.2006.08.025
pubmed: 17074498
Vyas H, Driscoll DJ, Cabalka AK et al (2007) Results of transcatheter Fontan fenestration to treat protein losing enteropathy. Catheter Cardiovasc Interv 69:584–589
doi: 10.1002/ccd.21045
pubmed: 17323361
Schafstedde M, Nordmeyer S, Schleiger A et al (2021) Persisting and reoccurring cyanosis after Fontan operation is associated with increased late mortality. Eur J Cardiothorac Surg 61(1):54–61
doi: 10.1093/ejcts/ezab298
pubmed: 34195822